Merck Signs a Second Oncology Collaboration with Highlight Therapeutics

 Merck Signs a Second Oncology Collaboration with Highlight Therapeutics

Merck Signs a Second Oncology Collaboration with Highlight Therapeutics

Shots:

  • The P-II Spotlight 203 study will evaluate the combination of BO-112 (intra-tumoral administration) + Keytruda (pembrolizumab) with CR or PR as its 1EPs. The study will evaluate disease control rates, DoR, PFS, OS, as well as safety, tolerability, and PK of the therapy in ~40 patients
  • The collaboration will focus on the evaluation of the combination therapy in patients that have progressed on anti-PD-1-based therapy in refractory advanced MM
  • The P-II study of combination therapy in patients with liver metastases from colorectal or gastric/GEJ cancer is currently under progress. Highlight Therapeutics has been dosed it first patient P-IIa study in liver metastasis

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post